Anzeige
Mehr »
Login
Sonntag, 22.12.2024 Börsentäglich über 12.000 News von 679 internationalen Medien
Breaking News: Vorweihnachtlicher Kaufrausch an der Börse?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14UCN | ISIN: US30050B1017 | Ticker-Symbol: 9EH
Tradegate
20.12.24
19:32 Uhr
10,800 Euro
-0,200
-1,82 %
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
EVOLENT HEALTH INC Chart 1 Jahr
5-Tage-Chart
EVOLENT HEALTH INC 5-Tage-Chart
RealtimeGeldBriefZeit
10,90011,00021.12.
10,90011,00020.12.
PR Newswire
19 Leser
Artikel bewerten:
(0)

Evolent Health, Inc.: Evolent announces Dr. Von Nguyen as incoming Chief Medical Officer, effective January 1

Finanznachrichten News

Longtime CMO Dr. Andrew Hertler to serve as senior advisor and CMO emeritus.

WASHINGTON, Dec. 18, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, announced the appointment of Dr. Von Nguyen as Chief Medical Officer, effective January 1, 2025.

Dr. Nguyen joined Evolent as Chief Clinical Officer in July 2024 after serving as clinical lead for population health at Google. Among other previous roles, he has been Chief Medical Officer at Blue Cross North Carolina, Deputy Associate Director of Policy and Strategy at the Centers for Disease Control and Prevention, and Senior Advisor at the Centers for Medicare and Medicaid Services, where he helped design value-based programs in specialty and primary care. Trained as a primary care physician, he has worked at clinics for underserved communities in the U.S. and internationally.

"Dr. Nguyen's unique mix of experiences in delivering patient care, shaping health policy and powering clinical innovation at scale position him well to lead Evolent's own clinical quality programs," said Evolent President Dan McCarthy. "As he has already demonstrated in his short time here, Von's background and skills, combined with his profound empathy for patients and his relentless passion for bringing fresh solutions to status quo challenges, will accelerate our efforts to create a higher-quality, more affordable and less fragmented healthcare system."

Dr. Nguyen will succeed Dr. Andrew Hertler, who will move to a part-time role as senior advisor and CMO emeritus after more than a decade at Evolent. Dr. Hertler, a medical oncologist with more than 40 years in the field, will focus on advancing innovation for Evolent's oncology management solution.

"Dr. Hertler is a giant in the field of value-based specialty care and improving patient outcomes, and I am honored to succeed him," said Dr. Nguyen. "I came to Evolent to help accelerate our mission of making care simpler, higher quality, more affordable and more connected for patients dealing with complex health conditions. Our team of over 1,500 doctors, nurses and allied clinicians wake up every day focused on this mission, and I look forward to working with them in my new role to build on Dr. Hertler's strong legacy in the future."

About Evolent

Evolent (NYSE: EVH) specializes in better health outcomes for people with complex conditions through proven solutions that make healthcare simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in healthcare nationally. Learn more about how Evolent is changing the way healthcare is delivered by visiting evolent.com.

Contacts

Media: Jamie Manfuso, [email protected]

Investors: Seth R. Frank, [email protected]

SOURCE Evolent Health, Inc.

© 2024 PR Newswire
6 Richtige für 2025
Das Börsenjahr 2025 klopft schon an die Tür – und wie immer geht es um die Frage: Welche Aktien werden die großen Gewinner sein? Die Auswahl an Möglichkeiten ist riesig, doch nur ein paar echte Volltreffer stechen heraus.

Ob stabiler Dividenden-Lieferant, Tech-Pionier oder spekulative Wette im Krypto-Bereich – wir haben die Märkte für Sie ausgiebig durchforstet und präsentieren Ihnen 6 Unternehmen, die große Chancen auf außergewöhnliche Kurssteigerungen besitzen. Hier sind, speziell für Sie, Ihre „6 Richtigen“ für 2025.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche Unternehmen das Potenzial besitzen, im kommenden Jahr richtig durchzustarten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.